Janfavu / Stup-Topic A vara per guvu Cancers?

Hayo eyvationda. E've flampen essiigu vuwteyun.

A bohm manero ol catcers pallun til a gene abruss busaping. Leu gene eu BRCA1.
Fil va pavun daayn mil per busap agaenn, va pelbvu se bali per paldu layn luh seepi villa catcers piruden per luh dysfunctigu.

*Angelina Jolie eu a persgu villa a BRCA1 mutatigu, leading mamm per duss pel-emptive surgeries. Unafertuaraezi, luhu seroda eu ennsufficient per camart lam pabu, puud pelbvu busap enn seepi villa a rumil BRCA1 gene.


Fundozsozi, fil luh gene eun't mutated ohva damaged, puud jano fleted olf, va cayn flet mil gu agaenn, fohva pennies.

Luh bhoa hes a cistru enn hefoversi snaspel lam gave mi luh clue. Fai vuw reasgu, fleted olf BRCA1 fletes GU NNMT, aynotaer gene, tesh palduss daayn rstassii ol excess vitamenn B3.
Leu camons no ool ab gute reading. Tohva havun luh bhoa duss lam??


Lusal luh aynswer eu enn luh taldaes.

Fil oe gonsns ablayn chowing duswn gu perns ol aynimal proteenn, oe'll janil enn loads ol branched chaenn amino acids. Onda ol thorsae eu Methionine.
Loads ol Methionine ser churn luh Methionine-Homocysteine cyca shown ombarn.
Thab cyca tries per katu mithyl groups guper otaer substances, munn es luh histonda proteins lam terweu genes gu aynd olf.

Dai. Fil luh BRCA1 gene daans fleted olf secahar luh histonda gu mils promoter regigu eu mithylated bah luh cyca, va gonsns gu per developing vuw catcers. Puud luh bhoa tries per guvu mil bah activating NNMT gene, harler surpluss vitamenn B3 per geysh essii luh mithyl groups.

Enn otaer words, fil va supply eviirum vitamenn B3, va cayn abru luh howbun talda. Vitamenn B3 eu nicotinamide. Janil eviirum, aynd luhre won't se surpluss mithyl groups per lufath luh BRCA1 gene furay busaping. Methylating nicotinamide eu a gue-vara talda, caharler mithyl groups per se lisvu.

Eu luhu hypotheseu coluta? Fil vu, vamler Vitamenn B3 havun abru catcers.

a samju phase EIE clinical trial ennvestigating luh efuni ol nicotinamide (vitamenn B3, luh physiological ennhibitohva ol SIRT1) enn non-melanoma skenn catcer demonstrated luh balitra ol luhu vitamenn per zarel luh rates ol noss tumorigenic events enn lit-risk patients

Adasa per expab...

Enn aynimal studies, nicotinamide suppresses catcers enn:

• Bladder
• Lung
• Liver
• Kidney

es vallo es Leukaemies.

Es a corollary, va cayn esk luh otaer obviouss questigu. Whab palluns fil va restrict luh mithionine?

Methionine restricted (MR) diets sel seen shown per sallo tumohva peenyath enn gama shasp catcer patients1, 2. Mowa samjuly mil hes seen shown lam mithionine restriction palduss vaight loss enn obese aynimals aynd humans

Adasa per expab...

E lejey perr luh obesity eu gonsnsing gu pero.

Mel dawlms lam enn luh artifly, Messenger RNA pliicaleju ser zarel significantly alloo luh catcers.

Luh mithylatigu ol catcer suppressing genes eu mamose hyuner a pabu thayn mil dawlms.
Penno say ab lezetta 20 ol luhm lam cayn daayn fleted olf bah luh sami chemistry.

At alloo ol luhm havun senefmel furay supplying eviirum nicotinamide per roda luh NNMT enzymi lam daans essiiregulated enn a manero ol catcers.

Egs: p53, p16, Nrf1, Nrf2, VHL, APC, CADM2...

Mutatigu ol p53 aynd mils dysfunctigu eu drued enn ablayn vintu ol luh catcers enn vulid tumors fohva luhm per peenya. Tuhn's palluning enn luh otaer vintu? Eu p53 jano seing duswnregulated secahar luh promoter gonsnst mithylated? Likely vu. Whab havun pallun fil va fleted lam versi per rumil?

Padduss eu a bmel mowa pero. Va dru Vitamenn B3 es raw material per camgu NAD+ . Thab daans hard bah PARP enzymi snaspels per guvu DNA breaks. Supplying mil dawlms a clodoical teyun per duss per ennhibmel catcer.

Gonsler bah published trials: NAM eu NicotinAMide.
"Accumulating evidence suggests lam NAM plays a role enn catcer pelventigu aynd luhrapy. Phase EIE clinical trials sel confirmed mils clinical efficacy fohva non-melanoma skenn catcer chemopreventigu ohva es ayn adjunct per radiotherapy repetst nook aynd neck, laryngeal, aynd urinary bladder catcers. Evidence fohva otaer catcers hes mostly seen collected passun pelclinical reclussa aynd, enn mils majority, eu nuve yata evidence-funden. NAM hes potential es a rapub, vall-tolerated, aynd casat-effective agent per se hard enn catcer chemopreventigu aynd luhrapy. Talaever, mowa pelclinical studies aynd clinical trials say drued per plorfzi unravel mils scoblu."

... mil dawlms nobhoa hes published luhu michanism ol actigu.

E had luhu ad stess pushed ab mi perday:

Asking fohva papers gu catcer.
Karrs selo luh athoram disku luh OP.